Ranking Profile - Guizhou Xinbang Pharmaceutical Co Ltd

Introduction

Guizhou Xinbang Pharmaceutical Co Ltd (Guizhou Xinbang Pharmaceutical) carries out research and development, manufacture and distribution of medical products. The company offers pharmaceutical manufacturing which is engaged in the manufacture and distribution of Chinese patent medicines, such as ginkgo leaves tablets, chinese herbal medicines, and chinese medicinal materials. It provides drugs for the cardiovascular, digestive system, endocrine, tumors and immunomodulators, blood system medication, Rheumatism and Rheumatoid, and Urinary system diseases among others. Guizhou Xinbang Pharmaceutical is headquartered in Guiyang, Guizhou Province China.

Company info

Country (HQ): China
Sector: Pharmaceuticals and Healthcare
Market Cap (US$ m): 1,349
Revenue (US$ m): 944 (2022)

Innovation ranking

307

Innovation score

Closest peers in the Pharmaceuticals and Healthcare sector

Innovation Ranking

Company
Headquarters
Sector

Johnson & Johnson

United States

Pharmaceuticals and Healthcare

F. Hoffmann-La Roche Ltd

Switzerland

Pharmaceuticals and Healthcare

Guizhou Xinbang Pharmaceutical Co Ltd

China

Pharmaceuticals and Healthcare

EyeGate Pharmaceuticals Inc

United States

Pharmaceuticals and Healthcare

Shin Poong Pharm Co Ltd

South Korea

Pharmaceuticals and Healthcare

Are you ranked? Get the Innovation Ranking Report

  • Company Ranking Report
    • If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
    • Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
    • Contextualised information on the company's standing in relation to peers
    • Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
    • Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
  • Rosettes
  • Certificate of Achievement
  • Press release
Screenshot of Deal Makers